IHI - ETF AI Analysis
Top Page
iShares U.S. Medical Devices ETF (IHI)
IHI, the iShares U.S. Medical Devices ETF, earns a solid overall rating thanks to major holdings like Medtronic, Intuitive Surgical, and Dexcom, which show strong financial performance, innovation, and generally positive momentum that support long-term growth. However, several key positions, including Abbott Laboratories and Stryker, face bearish or cautious technical signals and premium valuations, which can limit short-term upside. The main risk factor is the fund’s heavy concentration in a single industry—medical devices—meaning sector-specific challenges or regulatory changes could affect many of its holdings at once.
IHI vs. SPDR S&P 500 ETF (SPY)
- AUM
- 3.62B
- Region
- North America
- Expense Ratio
- 0.37%
- Beta
- 0.61
- Issuer
- iShares
- Inception Date
- May 01, 2006
- Dividend Yield
- 0.46%
- Asset Class
- Equity
- Index Tracked
- DJ US Select / Medical Equipment
IHI Summary
IHI is the iShares U.S. Medical Devices ETF, which follows the DJ US Select / Medical Equipment index. It invests in U.S. companies that make medical tools and technology used in hospitals and clinics, such as diagnostic machines, surgical equipment, and devices that help treat patients. Well-known holdings include Abbott Laboratories and Intuitive Surgical. Someone might invest in IHI to tap into the long-term growth of healthcare and to spread their money across many medical device companies instead of picking just one. A key risk is that it is heavily focused on one sector, so its value can rise or fall sharply with changes in the healthcare industry.
How much will it cost me?
This ETF has an expense ratio of 0.37%, which means you’ll pay about $3.70 per year for every $1,000 invested. That’s a bit higher than the average broad-market index ETF because this fund is more specialized, focusing on U.S. medical device companies in a specific sector.
What would affect this ETF?
IHI could benefit from ongoing advances in medical technology, an aging U.S. population that needs more healthcare, and stable or falling interest rates that support higher valuations for its large device makers like Abbott, Intuitive Surgical, and Medtronic. On the negative side, stricter healthcare regulations, pricing pressure from insurers and government programs, or economic slowdowns that reduce hospital spending could hurt demand for medical equipment, and the fund’s heavy focus on U.S. healthcare devices means it is sensitive to any sector-specific setbacks.
IHI Top 10 Holdings
IHI is essentially a bet on U.S. medical technology, with heavy exposure to a few big names. Intuitive Surgical and Medtronic have been rising lately, helping to pull the fund forward, while ResMed and Edwards Lifesciences add steady support with more consistent gains. On the flip side, Abbott looks mixed and Boston Scientific is clearly lagging, acting like a weight on performance. With all major holdings rooted in U.S. healthcare equipment, this ETF is tightly focused on one sector and a handful of influential stocks that largely set the tone for returns.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ABT | Abbott Laboratories | 18.06% | $675.15M | $183.77B | -10.89% | 73Outperform |
 ISRG | Intuitive Surgical | 14.62% | $546.64M | $149.75B | -18.23% | 78Outperform |
 MDT | Medtronic | 11.52% | $430.49M | $123.49B | 9.47% | 80Outperform |
 BDX | Becton Dickinson | 4.55% | $169.99M | $53.90B | 11.13% | 67Neutral |
 GEHC | GE Healthcare Technologies Inc | 4.58% | $171.31M | $34.62B | 6.14% | 78Outperform |
 IDXX | Idexx Laboratories | 5.37% | $200.65M | $43.42B | 6.69% | 78Outperform |
 EW | Edwards Lifesciences | 4.46% | $166.54M | $53.03B | 13.11% | 79Outperform |
 SYK | Stryker | 4.59% | $171.46M | $111.95B | -13.88% | 70Outperform |
 RMD | Resmed | 4.29% | $160.20M | $32.34B | -5.65% | 76Outperform |
 DXCM | Dexcom | 4.08% | $152.49M | $30.69B | 45.59% | 79Outperform |
IHI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IHI, the sentiment is Positive. The current price of 56.51 is above the 20-day moving average (MA) of 53.64, above the 50-day MA of 53.00, and above the 200-day MA of 53.40, indicating a bullish trend. The MACD of 0.87 indicates Negative momentum. The RSI at 66.67 is Neutral, neither overbought nor oversold. The STOCH value of 83.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IHI.
IHI Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IHI | $56.51 | $61.00(7.95% Upside) | $3.62B | 0.37% | 74Outperform |
 IYH | $77.60 | $84.20(8.50% Upside) | $4.71B | 0.37% | 73Outperform |
 FHLC | $88.24 | $98.15(11.23% Upside) | $3.95B | 0.08% | 71Outperform |
 FBT | $273.89 | $336.78(22.96% Upside) | $3.13B | 0.55% | 71Outperform |
 IHE | $106.92 | $126.72(18.52% Upside) | $1.62B | 0.37% | 70Neutral |
 IHF | $59.00 | $68.28(15.73% Upside) | $1.48B | 0.37% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IHI | iShares U.S. Medical Devices ETF | 56.51 | -4.22 | -6.95% | |
| IYH | iShares U.S. Healthcare ETF | 77.60 | 17.33 | 28.75% | |
| FHLC | Fidelity MSCI Health Care Index ETF | 88.24 | 19.38 | 28.14% | |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 273.89 | 83.79 | 44.08% | |
| IHE | iShares U.S. Pharmaceuticals ETF | 106.92 | 32.14 | 42.97% | |
| IHF | iShares U.S. Healthcare Providers ETF | 59.00 | 10.76 | 22.31% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.